<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570163</url>
  </required_header>
  <id_info>
    <org_study_id>EA1/043/20</org_study_id>
    <nct_id>NCT04570163</nct_id>
  </id_info>
  <brief_title>Berlin Registry of Right Heart Interventions</brief_title>
  <official_title>Berlin Registry of Right Heart Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study evaluates patients after interventional therapy of valvular diseases of the&#xD;
      right heart. Follow-up examinations include medical history taking, laboratory measurements&#xD;
      and an echo. The aim is to assess the different interventional therapies and their impact on&#xD;
      patient's outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subject of the study is to register interventional therapies of right heart diseases&#xD;
      (such as &quot;cardioband&quot; and &quot;edge-to-edge&quot; techniques of the tricuspid valve) performed in&#xD;
      Berlin/ Brandenburg (primarily at the Charité, Universitätsmedizin Berlin). Based on the&#xD;
      development and the increasing use of interventional therapies in tricuspid and pulmonary&#xD;
      valve diseases, the impact on the patients' symptoms and life expectancy after interventions&#xD;
      will be investigated. The aim is to identify patient subgroups that benefit the most.&#xD;
&#xD;
      Primary endpoints: Total mortality, cardiovascular mortality, heart failure hospitalization.&#xD;
&#xD;
      Secondary endpoints: NYHA class, NTproBNP, liver and kidney function (laboratory&#xD;
      measurements), valve function, cardiac function, and cardiac morphology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Years</target_duration>
  <primary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>Number of deceased participants after 2 months after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>Number of deceased participants after 2 months after intervention (cardiovascular cause of mortality)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unscheduled hospitalization for heart failure progression</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>Number of participants with unscheduled hospitalization for heart failure progression after 2 months after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>New York Heart Association (NYHA) class (to rate dyspnea in heart failure patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTproBNP</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>Laboratory measurement of NTproBNP 2 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>valve function</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>Echocardiographic quantification of valve function (proximal isovelocity surface area [PISA] method, effective regurgitant orifice [ERO], vena contracta [VC]) after 2 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>Laboratory measurement of bilirubin 2 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney function</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>Laboratory measurement of creatinine 2 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac function</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>Echocardiographic measurement of cardiac function (left ventricular ejection fraction, tricuspid anular plane systolic excursion) after 2 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac morphology</measure>
    <time_frame>2 months after intervention</time_frame>
    <description>Echocardiographic measurement of cardiac morphology (right ventricular and right atrial diameter) after 2 months after intervention</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <condition>Pulmonary Regurgitation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interventional therapy mainly of tricuspid regurgitation (TriClip, Cardioband)</intervention_name>
    <description>Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients after interventional therapy of valvular diseases of the right heart (such as&#xD;
        &quot;cardioband&quot; and &quot;edge-to-edge&quot; techniques of the tricuspid valve) performed in Berlin/&#xD;
        Brandenburg (primarily at the Charité, Universitätsmedizin Berlin).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with planned or recent valve interventions of the right heart (tricuspid&#xD;
             regurgitation/ stenosis, pulmonary regurgitation/ stenosis)&#xD;
&#xD;
          -  &gt;18 years&#xD;
&#xD;
          -  Written, documented consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in care or unable to consent&#xD;
&#xD;
          -  Patients who are unable to comply with follow-up examinations&#xD;
&#xD;
          -  Patients who are detained in an institution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Henryk Dreger, Prof. Dr. med.</last_name>
    <phone>+4930450613496</phone>
    <email>henryk.dreger@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henryk Dreger, Prof. Dr. med.</last_name>
      <phone>+49 (0) 30 450 61 34 96</phone>
      <email>henryk.dreger@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Henryk Dreger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>As part of the expected publications, it is planned to provide data of the study participants and more detailed information on inclusion and exclusion criteria (study protocol).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

